Yukiya Narita
Okazaki, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 96 publications
Clinical practice guidelines for duodenal cancer 2025.
Journal: Journal of gastroenterology
Published: July 31, 2026
Systemic therapy for esophageal adenocarcinoma:current status and challenges of targeted therapy and immunotherapy
Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
Published: June 10, 2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026
Development of a visualization tool to estimate out-of-pocket costs for systemic cancer therapy in Japan and claims-based agreement evaluation: the VEST-Ca study.
Journal: Japanese journal of clinical oncology
Published: February 05, 2026
Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: a case report.
Journal: Therapeutic advances in medical oncology
Published: January 13, 2026
ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.
Journal: Cancer research communications
Published: December 17, 2025
Regorafenib in refractory gastric cancer: modest median, meaningful milestone.
Journal: Journal of gastrointestinal oncology
Published: September 08, 2025
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study.
Journal: Japanese journal of clinical oncology
Published: September 03, 2025
Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study.
Journal: Therapeutic advances in gastroenterology
Published: August 25, 2025
Peripheral SNCA+ cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer.
Peripheral SNCA+ cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer.
Journal: Discover oncology
Published: July 24, 2025
IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer.
Journal: Journal of translational medicine
Published: July 01, 2025
The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: June 10, 2025
Last Updated: 09/26/2026